ImmunGene Receives $9,000,000 Series A Financing

  • Feed Type
  • Date
    11/8/2013
  • Company Name
    ImmunGene
  • Mailing Address
    558 St. Charles Dr Thousand Oaks, CA 93012
  • Company Description
    ImmunGene is focused on creating a pipeline of next generation antibody therapeutics, based on its platform technology of antibody fusions with select cytokines, chemokines and costimulatory molecules, to attract, deplete or activate the powerful cells of the immune system at the site of disease.
  • Website
    http://www.immungene.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $9,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies.
  • M&A Terms
  • Venture Investor
    Ally Bridge Group